Key Opinion Leader: Dr. Dave Singh’s Impact on Pulmonology and Immunology
Who is Dr. Dave Singh?
Dr. Dave Singh is a leading healthcare professional whose specialty is pulmonology and immunology. He works at the University of Manchester, where he teaches Respiratory Pharmacology as a senior lecturer. According to the Manchester University website, his interests include “research interests are the pharmacotherapy of Asthma and COPD with studies spanning from basic pharmacology investigations of anti-inflammatory drug action to clinical trials.”
What is his specialty?
Dr. Singh specializes in pulmonary disease and immunology. According to the British Pharmacological Society, his research interest is “the development of new drugs for asthma and COPD.”
What work is he currently doing?
Dr. Singh currently teaches clinical pharmacology & respiratory medicine at the University of Manchester. According to the British Pharmacological Society, “he is the medical director of the Medicines Evaluation Unit, where he has acted as principal investigator in over 300 clinical trials. He is a member of the Global initiative for the management of chronic Obstructive Lung Disease (GOLD) Science Committee, and currently is the chair of the European Respiratory Society airway pharmacology group.” He is currently leading four clinical trials, two of which have to do with the coronavirus.
Social Media Presence
While Dr. Singh does not have an active LinkedIn or Twitter presence, he has had 1,600 social media mentions stemming from the span of his career.
What is his research background?
Dr. Singh has co-authored a total of 671 publications throughout the span of his tenure so far. He has participated in 74 clinical trials. The top conditions for those trials have been Pulmonary Disease and COPD, and the top interventions for the trials were Tiotropium Inhalation Solution and Placebo
H1 appreciates and celebrates Dr. Singh’s hard work in immunology and pulmonology, as well as the hard work he’s invested in the many clinical trials he has led. We excitedly await additional updates from his trials, his work, and his positive impact in the immunology and pulmonology space, and we thank him for his contributions.